OCUPHIRE PHARMA INC. - COMMON STOCK
1,2900
27-сентября-24 14:59:54
15 мин. задержка
Акции
-0,0100
-0,77%
Сегодняшний диапазон
1,2502 - 1,3050
ISIN
N/A
Источник
NASDAQ
- Котировки
- Графики
Новости
- Статистика
-
08 мар 2022 07:00:02 Источник Nasdaq GlobeNewswire
-
08 фев 2022 07:00:02 Источник Nasdaq GlobeNewswire
-
31 янв 2022 05:00:00 Источник Nasdaq GlobeNewswire
-
Ocuphire to Host Virtual Investor R&D Day on January 31st
25 янв 2022 06:00:01 Источник Nasdaq GlobeNewswire
-
05 янв 2022 06:00:01 Источник Nasdaq GlobeNewswire
-
08 дек 2021 07:00:01 Источник Nasdaq GlobeNewswire
-
23 ноя 2021 08:00:01 Источник Nasdaq GlobeNewswire
-
Ocuphire Announces Financial Results for the Third Quarter 2021 and Provides Corporate Update
12 ноя 2021 06:00:02 Источник Nasdaq GlobeNewswire
-
01 ноя 2021 08:30:31 Источник Nasdaq GlobeNewswire
-
07 окт 2021 06:00:01 Источник Nasdaq GlobeNewswire
-
01 окт 2021 07:49:48 Источник Nasdaq GlobeNewswire
-
Ocuphire Pharma Presenting at Three Upcoming Healthcare Conferences This Fall
27 сен 2021 06:00:00 Источник Nasdaq GlobeNewswire
-
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03 сен 2021 16:00:00 Источник Nasdaq GlobeNewswire
-
Ocuphire Pharma Presenting at Four Conferences in September
02 сен 2021 06:00:02 Источник Nasdaq GlobeNewswire
-
Ocuphire Announces Financial Results for the Second Quarter 2021 and Provides Corporate Update
12 авг 2021 06:00:01 Источник Nasdaq GlobeNewswire
-
Ocuphire Pharma Presenting at Two Conferences in August
06 авг 2021 06:30:00 Источник Nasdaq GlobeNewswire
-
22 июл 2021 07:00:02 Источник Nasdaq GlobeNewswire
-
Ocuphire Selected to Present at Multiple Ophthalmic Conferences in July
13 июл 2021 08:00:01 Источник Nasdaq GlobeNewswire
-
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09 июл 2021 16:00:00 Источник Nasdaq GlobeNewswire
-
Ocuphire’s VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary Endpoints
30 июн 2021 06:15:00 Источник Nasdaq GlobeNewswire